Search clinical trials for: Palbociclib Taselisib / Pictilisib

Total 356 results

Royal Marsden NHS Foundation Trust
Pfizer; Roche Pharma AG; Institute of Cancer Research, United Kingdom

Unknown

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)

Breast Cancer | Advanced Solid Tumours

United Kingdom
Centre Hospitalier Universitaire Dijon

Terminated

Trial of Taselisib in Overgrowth (TOTEM)

PIK3CA-Related Overgrowth

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Genentech, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Sudipto Mukherjee

Active, not recruiting

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaborators

Terminated

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
Centocor, Inc.

Completed

A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers

Healthy
Pfizer

Completed

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

Healthy

United States
Pfizer

Completed

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

Healthy

United States
Megalabs

Not yet recruiting

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

Bioequivalence
Pfizer

Completed

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
Pfizer

Completed

Relative Bioavailability For Palbociclib Formulations

Healthy

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Sarcoma | Liposarcoma

United States
Pfizer

Completed

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Healthy

United States
Pfizer

Completed

A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

Healthy

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Pfizer

Completed

Study Of Palbociclib (PD-0332991) In Renal Impairment

Renal Impairment

United States
Pfizer

Completed

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

Healthy

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

Hormone Receptor Positive Advanced Breast Cancer

China
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Pfizer

Completed

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Metastatic Breast Cancer

Israel
Pfizer

Recruiting

Swedish Ibrance Registries Insights (SIRI) (SIRI)

Malignant Neoplasm of Breast

Sweden
Pfizer

Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of Breast

India
InventisBio Co., Ltd

Completed

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States, China
University of Nebraska

Recruiting

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Breast Cancer

United States
Pfizer

Recruiting

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (PERFORM)

Breast Neoplasms

Austria, Germany
Razelle Kurzrock, MD

Withdrawn

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

Cancer, Advanced

United States
University of Milano Bicocca

Completed

Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer (ETIC)

DILI

Italy
Brown University
Taiho Oncology, Inc.

Recruiting

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Soft Tissue Sarcoma | Advanced Breast Cancer | SCLC | Bladder Cancer | Endometrial Cancer | Treatment-Refractory Solid Tumors | Retinoblastoma Deficiency

United States
Pfizer

Completed

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
Fundacion Oncosur
Pfizer; Apices Soluciones S.L.; Pierre Fabre Ibérica, S.A.

Completed

Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PALBOBIN)

Triple Negative Breast Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)

Pancreatic Neuroendocrine Cancer

Spain
Pfizer

Completed

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Healthy

United States
Pfizer

Active, not recruiting

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Breast Cancer

Denmark
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
NiKang Therapeutics, Inc.
Pfizer

Recruiting

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Neoplasms | Kidney Cancer | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Kidney Diseases | Urologic Diseases | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recurrent... and other conditions

United States
Namik Kemal University

Not yet recruiting

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

Turkey
Maastricht University Medical Center
Netherlands Thrombosis Foundation

Completed

Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis (Resolve-DVT)

Deep Vein Thrombosis

Netherlands
Pfizer

Active, not recruiting

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Metastatic Breast Cancer

United States
Washington University School of Medicine
Pfizer

Completed

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Carcinoma, Squamous Cell of Head and Neck

United States
Pfizer

Active, not recruiting

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Metastatic Breast Cancer

Korea, Republic of
Calithera Biosciences, Inc

Completed

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NSCLC | Solid Tumors | KRAS Gene Mutation | CRC

United States
ETOP IBCSG Partners Foundation
Pfizer

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Breast Cancer Recurrent

Switzerland, Italy, France, Spain, Hungary, Austria
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc) | Papillary Renal Cell Carcinoma (Prcc)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
Arvinas Estrogen Receptor, Inc.
Pfizer

Recruiting

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)

Breast Cancer

United States
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine

3

Subscribe